Nov 17, 2022

Featuring an interview with Dr Eytan Stein, including the following topics:

• Practical considerations for using venetoclax/HMA (hypomethylating agent) combinations in the management of acute myeloid leukemia (AML) (0:00)
• Approach to transplant for older patients with AML (10:33)
• Potential availability of magrolimab and sabatolimab in clinical practice (13:04)
• ASH 2022 preview: Investigational therapies excluding transplantation and cellular immunotherapies (17:33)
• Activity, tolerability and future directions with FLT3 and IDH inhibitors in AML (22:29)

CME information and select publications